RALEIGH, N.C.--(BUSINESS WIRE)--BioDelivery Sciences International, Inc. (Nasdaq:BDSI) today announced it will present a pharmacokinetic study for its lead product, BEMA™ Fentanyl, a potential treatment for breakthrough pain (BTP) in opioid-tolerant cancer patients at the 24th Annual Meeting of the American Academy of Pain Medicine in Orlando, Florida. In January 2008, BioDelivery Sciences announced that the U.S. FDA accepted for filing the company’s New Drug Application for BEMATM Fentanyl. A determination from the FDA on this NDA is expected in August 2008.
